sellWeak cluster of 410b5-1 plan
Daniel Karlin sold $49k of DFTX
Chief Medical Officer at Definium Therapeutics, Inc.. 6,643 shares at an average of $7.43, traded Dec 26, 2024, filed Dec 27, 2024.
Warning score
17Value
$49k
6,643 shares
Holdings after
338,013
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +7Trade size$49k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-132164, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 26, 2024 | SOpen-market sale Common Shares10b5-1 | -6,643 | $7.43 | $49k | 338,013 | Dec 27, 2024 |
Related signals
Other insiders at Definium Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $1.2M 31,550 shares | -1% | |
| 27Weak | Definium Therapeutics, Inc. | Brandi Roberts Chief Financial Officer | $123k 3,377 shares | -1% | |
| 28Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $514k 14,051 shares | -3% | |
| 20Weak | Definium Therapeutics, Inc. | Matthew T. Wiley Chief Commercial Officer | $113k 3,097 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $397k 10,853 shares | -1% | |
| 26Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $722k 19,023 shares | -1% | |
| 37Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $451k 24,431 shares | -3% | |
| 22Weak | Definium Therapeutics, Inc. | Mark Sullivan Chief Legal Officer | $198k 10,702 shares | -4% | |
| 21Weak | Definium Therapeutics, Inc. | Daniel Karlin Chief Medical Officer | $148k 8,018 shares | -2% | |
| 35Weak | Definium Therapeutics, Inc. | Robert Barrow Chief Executive Officer | $339k 25,791 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.